Comparative Pharmacology
Head-to-head clinical analysis: NAVANE versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAVANE versus QUIDE.
NAVANE vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene neuroleptic; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic blocking, and sedative effects.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
Oral: 10-20 mg three times daily; maximum 160 mg/day. IM (acute): 5-10 mg every 4-6 hours; maximum 30 mg/day.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 20-24 hours, allowing for once-daily dosing. Steady-state reached in 4-5 days.
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Primarily hepatic metabolism; approximately 20-30% excreted renally as metabolites, <1% unchanged. Biliary/fecal excretion accounts for ~50% of metabolites.
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic, Typical
Antipsychotic